ZEO ScientifiX (OTCQB: ZEOX) expands medical advisory board for regenerative medicine push

Filing Impact

(Moderate)

Filing Sentiment

(Neutral)

Form Type

8-K

Rhea-AI Filing Summary

ZEO ScientifiX, Inc. expanded its Medical Advisory Board by adding nine physicians and scientific innovators across disciplines such as orthopedics, oncology, longevity science, pain management, plastic surgery, and advanced biologic therapies. The board is positioned as a core scientific body focused on research, clinical protocols, and high clinical standards rather than marketing endorsements.

The advisors will guide scientific development, regenerative biologics, and physician education, including programs like the Physician-Led Patient Masterclass and initiatives connected to the $101 million XPRIZE Healthspan longevity prize competition, where the company is a semi-finalist. ZEO ScientifiX describes itself as a clinical-stage biopharmaceutical company focused on regenerative biologics and physician education.

8-K Event Classification

2 items: 8.01, 9.01

2 items

Item 8.01 Other Events Other

Voluntary disclosure of events the company deems important to shareholders but not covered by other items.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

Key Figures

New advisors added: 9 physicians and scientific innovators XPRIZE Healthspan competition scale: $101 million

2 metrics

New advisors added 9 physicians and scientific innovators Expansion of Medical Advisory Board announced June 9, 2026

XPRIZE Healthspan competition scale $101 million ZEO ScientifiX named semi-finalist in longevity prize competition

Key Terms

regenerative medicine, Medical Advisory Board, clinical-stage biopharmaceutical, regenerative biologics, +2 more

6 terms

regenerative medicine medical

"leaders in regenerative and longevity medicine"

A field of medical treatments that aims to repair, replace or regenerate damaged tissues and organs using approaches such as cell or gene therapies, engineered tissues, and biologically active materials. It matters to investors because successful regenerative therapies can create entirely new, high-value markets and replace chronic treatments, offering large potential returns but also long development timelines, heavy regulation and high technical risk—like betting on a promising new technology that could either revolutionize care or fail in trials.

Medical Advisory Board financial

"expansion of its Medical Advisory Board with the addition of nine"

clinical-stage biopharmaceutical financial

"an SEC-reporting, clinical-stage biopharmaceutical company focused on"

A clinical-stage biopharmaceutical is a company that is developing medicines or biological treatments that are currently being tested in people in clinical trials to assess safety and effectiveness. For investors it signals a higher-risk, higher-reward profile: progress through human testing and regulatory milestones can sharply increase value if results are positive, while failed trials can wipe out expected future revenue — like a prototype that must prove it works before it can be sold widely.

regenerative biologics medical

"focused on the research, development, and manufacturing of regenerative biologics"

forward-looking statements regulatory

"Certain statements contained in this press release should be considered forward-looking statements"

Forward-looking statements are predictions or plans that companies share about what they expect to happen in the future, like estimating sales or profits. They matter because they help investors understand a company's outlook, but since they are based on guesses and assumptions, they can sometimes be wrong.

XPRIZE Healthspan longevity prize competition other

"tied to industry initiatives such as the XPRIZE Healthspan longevity prize competition"

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Understanding 8-K Material Events →

06/09/2026 - 07:05 AM

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934

Date of report (Date of earliest event reported): June 9, 2026

ZEO SCIENTIFIX, INC.

(Exact name of registrant as specified in its charter)

Nevada		000-55008		47-4180540
(State or Other Jurisdiction of Incorporation)		(Commission File Number)		(IRS Employer Identification No.)

3321 College Avenue, Suite 246 Davie, Florida		33314
(Address of Principal Executive Offices)		(Zip Code)

Registrant’s telephone number, including area code: (888) 963-7881

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each Class		Trading Symbol		Name of each exchange on which registered
None		N/A		N/A

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

As used in this Current Report on Form 8-K (this “Report”), and unless otherwise indicated, the terms “the Company,” “ZEO,” “we,” “us” and “our” refer to Zeo ScientifiX, Inc.

Item 8.01 Other Events.

On June 9, 2026, ZEO issued a press release announcing the expansion of its Medical Advisory Board with the addition of nine physicians and scientific innovators across key disciplines in regenerative and longevity medicine.

A copy of the press release is included as Exhibit 99.1 to this Report.

Item 9.01 Financial Statements and Exhibits.

(d)

Exhibits

Exhibit No.		Description
99.1		Press Release, dated June 9, 2026
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: June 9, 2026	ZEO SCIENTIFIX, INC.

	By:	/s/ Ian T. Bothwell
		Ian T. Bothwell Chief Executive Officer and Chief Financial Officer

Exhibit 99.1

ZEO ScientifiX Expands Medical Advisory Board with Leaders in Regenerative and Longevity Medicine
Company strengthens scientific leadership as regenerative medicine gains national momentum

DAVIE, FLORIDA — June 9, 2026 — ZEO ScientifiX, Inc. (OTCQB: ZEOX) (“ZEO ScientifiX” or the “Company”), a biologics research and products company and a leader in educating physicians on the science of regenerative medicine, today announced the expansion of its Medical Advisory Board with the addition of nine highly-recognized physicians and scientific innovators across key disciplines in regenerative and longevity medicine. As access to regenerative medicine in the United States expands, with states such as Georgia and Tennessee and others expected to follow Florida in advancing supportive legislation, ZEO ScientifiX continues to focus on deepening its scientific foundation by assembling a multidisciplinary advisory board spanning orthopedics, oncology, longevity science, pain management, plastic surgery, and advanced biologic therapies.

The Company’s Medical Advisory Board now represents a growing network of physicians, researchers, and clinical specialists committed to advancing scientific rigor, clinical standards, and physician education in a rapidly evolving field.

Leading With Research, Not Marketing

Since its founding, ZEO ScientifiX has taken a deliberate approach to growth: build the science first and then share its knowledge with the medical community.

The Company’s Medical Advisory Board is not an endorsement vehicle. It serves as a core scientific body that researches clinical protocols currently used in the medical field, evaluates emerging research, and ensures that all physician-facing education and biologic offerings meet the highest standards of clinical integrity.

The newly expanded board reflects that commitment at scale.

New Advisory Board Members

The newly appointed advisors include:

●

Andrea Asseff-Llanes, DDS — board-certified dentist specializing in regenerative dental medicine

●

Elizabeth Parrish — founder and CEO of BioViva Sciences and a pioneer in gene-based longevity biotechnology

●

Faryal Farooqi, MD — physician specializing in longevity medicine and metabolic health

●

Michael Swartzon, MD — board-certified orthopedic sports medicine physician

●

Mark A. Rosenberg, MD — president and medical director of Advanced Medical Therapeutics and Integrative Cancer Therapeutics

●

Constantino Mendieta, MD — board-certified plastic surgeon known for innovations in regenerative surgical approaches

●

Neel Amin, MD — board-certified anesthesiologist and interventional pain medicine specialist; founder of Advanced Relief Institute

●

David Karli, MD — board-certified orthopedic surgeon and regenerative medicine researcher

●

Jacob Sanchez, CRNA, APRN — founder and CEO of Get Refreshed and certified registered nurse anesthesiologist specializing in aesthetic medicine and provider education.

They join an existing board that includes George C. Shapiro, MD, FACC, Zeo’s Chief Medical Officer and a director, who serves as Chairman of the Medical Advisory Board, along with other leading clinicians and researchers.

Advancing Clinical Innovation and Physician Education

Members of the Medical Advisory Board will provide strategic guidance on scientific development, clinical protocols, and physician education initiatives. They will also serve as faculty in ZEO ScientifiX educational programming, including the Physician-Led Patient Masterclass, as well as select programming tied to industry initiatives such as the XPRIZE Healthspan longevity prize competition, where ZEO ScientifiX was named a $101 million semi-finalist, and speaker engagements at the A4M Longevity Conferences.

“Medicine has traditionally focused on treating disease after it appears,” said Dr. George C. Shapiro. “Our long-term goal is to better understand and influence the biological systems that drive aging itself. Building a medical advisory board of this caliber reflects ZEO ScientifiX’s commitment to advancing regenerative medicine responsibly and with scientific discipline.”

Dr. Mark A. Rosenberg added: “I am excited to join the Medical Advisory Board for ZEO ScientifiX. The company is helping pioneer the next generation of regenerative medicine, and I’m honored to participate in advancing innovative therapies responsibly.”

Dr. Neel Amin added: “Biologic therapies represent one of the most exciting frontiers in modern healthcare. Our ability to harness cellular signaling to repair tissue, reduce inflammation, and restore function has the potential to fundamentally change how we treat chronic pain and degenerative conditions.”

A Board Built for What Comes Next

The regenerative medicine landscape is expanding rapidly, bringing both opportunity and variability in clinical quality, product standards, and patient education.

ZEO ScientifiX’s Medical Advisory Board will have a core goal of helping define and uphold those standards. The Company believes that as it continues to expand its physician network and scale its educational platforms, the depth and expertise of the Medical Advisory Board will serve as a direct resource for physician partners navigating the future of regenerative care.

Physicians interested in learning more about ZEO ScientifiX’s educational programs and partnership opportunities are encouraged to contact the Company directly.

About ZEO ScientifiX (OTCQB: ZEOX)

ZEO ScientifiX, Inc. (OTCQB: ZEOX) is an SEC-reporting, clinical-stage biopharmaceutical company focused on the research, development, and manufacturing of regenerative biologics. Operating out of Nova Southeastern University’s Center of Collaborative Research, the Company translates emerging science into scalable clinical solutions. ZEO ScientifiX supplies clinicians seeking to drive clinical excellence and sustainable practice growth through its cutting-edge biologics and regenerative therapies. For more information, visit https://zeoscientifix.com.

Forward-Looking Statements

Certain statements contained in this press release should be considered forward-looking statements within the meaning of the Securities Act of 1933, as amended, the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. These forward-looking statements involve known and unknown risks and uncertainties. Although the Company believes that the expectations reflected in these forward-looking statements are reasonable, they do involve assumptions, risks, and uncertainties, and these expectations may prove to be incorrect. Actual results could vary dramatically. ZEO ScientifiX has no intention and specifically disclaims any duty to update the information in this press release.

Media Contact

ZEO ScientifiX, Inc.
Karlista Maroney
Director of Growth Strategy
ir@zeoscientifix.com

Source: View Original Filing on SEC EDGAR

FAQ

What did ZEO ScientifiX (ZEOX) announce in this 8-K filing?

ZEO ScientifiX announced it expanded its Medical Advisory Board by adding nine physicians and scientific innovators. The board spans orthopedics, oncology, longevity science, pain management, plastic surgery, and advanced biologic therapies, focusing on research, clinical standards, and physician education in regenerative medicine.

How does the new Medical Advisory Board support ZEOX’s regenerative medicine strategy?

The Medical Advisory Board provides scientific guidance on regenerative biologics, clinical protocols, and physician education. Its members help evaluate emerging research, shape educational programs, and support ZEO ScientifiX’s goal of advancing regenerative medicine with strong clinical rigor and responsible implementation across multiple medical specialties.

What role will ZEO ScientifiX’s advisors play in physician education programs?

Advisors will serve as faculty for ZEO ScientifiX educational programs, including the Physician-Led Patient Masterclass. They will also contribute to select industry initiatives, supporting clinicians who want to adopt regenerative biologic therapies while maintaining high standards of patient care and scientific integrity in practice.

How is ZEO ScientifiX (ZEOX) involved with the XPRIZE Healthspan competition?

ZEO ScientifiX was named a $101 million semi-finalist in the XPRIZE Healthspan longevity prize competition. Members of its Medical Advisory Board are expected to support related programming and thought leadership as the company explores innovations in longevity-focused regenerative medicine and biologic therapies.

What type of company is ZEO ScientifiX and what does it focus on?

ZEO ScientifiX is an SEC-reporting, clinical-stage biopharmaceutical company focused on regenerative biologics. It operates from Nova Southeastern University’s Center of Collaborative Research, translating emerging science into scalable clinical solutions and supplying clinicians with biologic products and education aimed at improving outcomes and practice growth.

Why does ZEO ScientifiX emphasize research over marketing in regenerative medicine?

ZEO ScientifiX states its strategy is to build the science first and then share knowledge with physicians. The Medical Advisory Board is described as a scientific body, not an endorsement vehicle, tasked with reviewing clinical protocols, emerging research, and ensuring offerings reflect strong clinical integrity standards.

Filing Exhibits & Attachments

4 documents

Press Releases

EX-99.1 EXHIBIT 99.1 17.0 KB